10357-68-3

Basic information

• Product Name: 8-BROMOXANTHINE
• Synonyms: 8-BROMOXANTHINE;8-BROMOXANTHINE, HPLC PURIFIED, 98% PURE WITH HPLC UV CHROMATOGRAM;8-BroMo-1H-purine-2,6(3H,7H)-dione;NSC 24131;8-Bromopurine-2,6-diol;8-Bromo-1H-purine-2,6(3H,7H)
• CAS NO: 10357-68-3
• Molecular Formula: C₅H₃BrN₄O₂
• Molecular Weight: 231.01
• Mol File: 10357-68-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 2.118 g/cm³
• Refractive Index: 2.036
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: DMSO, Methanol
• PKA: 6.87±0.70(Predicted)
• CAS DataBase Reference: 8-BROMOXANTHINE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-BROMOXANTHINE(10357-68-3)
• EPA Substance Registry System: 8-BROMOXANTHINE(10357-68-3)

Safety Data

• Hazardous Substances Data: 10357-68-3(Hazardous Substances Data)

Usage

Uses

8-Bromoxanthine is used to study Arsenite-?inhibited xanthine oxidase.

InChI:InChI=1/C5H3BrN4O2/c6-4-7-1-2(8-4)9-5(12)10-3(1)11/h1H,(H2,7,8,9,10,11,12)

Upstream product

• 69-89-6 xanthin 

Downstream Products

• 2476-54-2 8-thioxo-8,9-dihydro-1H-purine-2,6(3H,7H)-dione 

Relevant articles and documents

Development of a carbon-11 PET radiotracer for imaging TRPC5 in the brain

The transient receptor potential channel subfamily member 5 (TRPC5) is a calcium permeable cation channel widely expressed in the brain. Accumulating evidence indicates that it plays a crucial role in psychiatric disorders including depression and anxiety. Positron emission tomography (PET) combined with a TRPC5 specific radioligand may provide a unique tool to investigate the functions of TRPC5 in animal disease models to guide drug development targeting TRPC5. To develop a TRPC5 PET radiotracer, the potent TRPC5 inhibitor HC608 was chosen for C-11 radiosynthesis through the N-demethyl amide precursor 7 reacting with [11C]methyl iodide. Under optimized conditions, [11C]HC608 was achieved with good radiochemical yield (25 ± 5%), high chemical and radiochemical purity (>99%), and high specific activity (204-377 GBq μmol-1, decay corrected to the end of bombardment, EOB). The in vitro autoradiography study revealed that [11C]HC608 specifically binds to TRPC5. Moreover, initial in vivo evaluation of [11C]HC608 performed in rodents and the microPET study in the brain of non-human primates further demonstrated that [11C]HC608 was able to penetrate the blood brain barrier and sufficiently accumulate in the brain. These results suggest that [11C]HC608 has the potential to be a PET tracer for imaging TRPC5 in vivo.

SUBSTITUTED XANTHINE DERIVATIVES

The present invention relates to compounds of formula (I) a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.

AZACYCLOHEXANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Azacyclohexane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.